Results 171 to 180 of about 5,080,573 (227)
Cost-effectiveness analysis of ibrutinib plus venetoclax for relapsed or refractory mantle cell lymphoma in China and the United States. [PDF]
Front Public HealthHe J, Liu X, Yang Q.
europepmc +1 more source
Correction to 'Mucin 20 Modulates Proteasome Capacity Through c-Met Signalling to Increase Carfilzomib Sensitivity in Mantle Cell Lymphoma'. [PDF]
J Cell Mol Medeuropepmc +1 more source
Annals of Oncology, 2013 Central nervous system (CNS) involvement in mantle cell lymphoma (MCL) is uncommon, and the manifestations and natural history are not well described.We present the data on 57 patients with MCL who developed CNS involvement, from a database of 1396 ...
Pavel Klener +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Critical Reviews in Oncology/Hematology, 2012
MCL is a well-characterized clinically aggressive lymphoma with a poor prognosis. Recent research findings have slightly improved the outcome of this neoplasm. The addition of rituximab to conventional chemotherapy has increased overall response rates, but it does not improve overall survival with respect to chemotherapy alone.
Cortelazzo S +3 more
openaire +5 more sources
MCL is a well-characterized clinically aggressive lymphoma with a poor prognosis. Recent research findings have slightly improved the outcome of this neoplasm. The addition of rituximab to conventional chemotherapy has increased overall response rates, but it does not improve overall survival with respect to chemotherapy alone.
Cortelazzo S +3 more
openaire +5 more sources
The Lancet Oncology, 2001
During the past decade, mantle-cell lymphoma has been established as a new disease entity. The normal counterparts of the cells forming this malignant lymphoma are found in the mantle zone of the lymph node, a thin layer surrounding the germinal follicles.
I, Barista +2 more
openaire +2 more sources
During the past decade, mantle-cell lymphoma has been established as a new disease entity. The normal counterparts of the cells forming this malignant lymphoma are found in the mantle zone of the lymph node, a thin layer surrounding the germinal follicles.
I, Barista +2 more
openaire +2 more sources
Treatment of Mantle-Cell Lymphoma
New England Journal of Medicine, 2022[No Abstract Available]
Burhan, Ferhanoglu +2 more
openaire +5 more sources
Current Opinion in Hematology, 2004
Mantle cell lymphoma is the B-cell lymphoma with the worst prognosis. Until now, no standard treatment has resulted in cure. Improvements in understanding of the disease are needed to advance therapeutic efforts.Pathology and immunohistochemistry can identify the subset of patients with the worse prognosis.
Francesco, Bertoni +2 more
openaire +2 more sources
Mantle cell lymphoma is the B-cell lymphoma with the worst prognosis. Until now, no standard treatment has resulted in cure. Improvements in understanding of the disease are needed to advance therapeutic efforts.Pathology and immunohistochemistry can identify the subset of patients with the worse prognosis.
Francesco, Bertoni +2 more
openaire +2 more sources
1997
MCLs are thought to arise from a subset of B cells that normally express the CD5 antigen and that reside in the mantle zone of secondary lymphoid follicles. Although expression of the CD5 antigen is also seen in small lymphocytic lymphoma and chronic lymphocytic leukemia, MCL differs from SLL/ CLL in several ways.
M A, Rodriguez, W C, Pugh
openaire +2 more sources
MCLs are thought to arise from a subset of B cells that normally express the CD5 antigen and that reside in the mantle zone of secondary lymphoid follicles. Although expression of the CD5 antigen is also seen in small lymphocytic lymphoma and chronic lymphocytic leukemia, MCL differs from SLL/ CLL in several ways.
M A, Rodriguez, W C, Pugh
openaire +2 more sources